A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those ...
The goal of SPS3 was to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback